The treatment dramatically inhibited the serum antibody response of anti-TP15, TP17, TP47 and TRUST titres tested in the patients of early syphilis and confirmed NS while only TP17 and TP47 antibodies significantly decreased in the patients of late syphilis and probable NS (Supplemental Table 5). The gene discussed is CDKN2B; the disease is syphilis.